The answer so far

In plain English: a laboratory result can show that something happens under controlled conditions. A treatment still needs evidence in people, with a suitable product, comparison, dose, and outcome. Follow the path in from laboratory model to people and then see what approval means.

A laboratory result answers a narrow question in a controlled setting. A treatment has to answer a much larger set of questions in people: does the target matter in the disease, does enough product reach it, does the effect survive the complexity of a human body, and are benefits larger than harms for a defined population? A promising result can therefore be real and still fail to become a useful treatment.1

On this page
  1. A model deliberately leaves things out
  2. The molecule has to get there
  3. The outcome has to matter
  4. A benefit can come with unacceptable trade-offs
  5. A real example: CEP-1347 in Parkinson disease
  6. Controls can make the claim narrower and stronger
  7. Follow the chain of questions
  8. Stopping is also information
  9. Read “promising” as an invitation to ask more
  10. Target engagement is a bridge, not a verdict
  11. Sources
Follow this question
Why can a promising laboratory result fail? Choose a step to explore this subject in more detail.
  1. 1A model deliberately leaves things out
  2. 2The molecule has to get there
  3. 3The outcome has to matter
  4. 4A benefit can come with unacceptable trade-offs

A model deliberately leaves things out

An in-vitro experiment might show that a molecule binds a receptor, slows an enzyme, or protects cultured cells from a stress. That is evidence about a mechanism under chosen conditions. It does not establish that the target drives illness in a person, that the same concentration can be reached safely, or that changing the pathway improves how people feel, function, or survive.

An animal model adds an intact organism, but it remains a model. Species differ in metabolism, immune responses, anatomy, disease course and behaviour. An induced injury or engineered mutation may reproduce one feature of a human disease while omitting others. The useful question is which aspect it represents, which it leaves out, and whether the study was designed and reported well enough to support the next experiment.18

The molecule has to get there

A substance can affect a target in a laboratory yet fail to reach it in a person at a useful and tolerable exposure. Absorption, distribution, metabolism and excretion change the journey. A short pulse, continuous exposure and treatment after established disease are different interventions even when the molecule is identical.

ICH M3(R2) describes nonclinical pharmacology, toxicology and pharmacokinetic studies used to support human trials and marketing authorisation. It is a framework for decisions, not a guarantee that an animal exposure predicts a therapeutic human exposure.28

The outcome has to matter

A biomarker can help researchers investigate a mechanism. Whether changing it reliably predicts a meaningful clinical outcome is a separate question. Later trials need a defined population, an appropriate comparator, outcomes that matter to patients, and follow-up long enough to observe benefit and harm. Ask what was measured, whether that measurement was the intended target of the study, and what interpretation it supports.34

A benefit can come with unacceptable trade-offs

Development evaluates adverse effects as well as the desired response. Sometimes the exposure needed for an effect cannot be used safely; sometimes the overall clinical result is less useful than hoped. A convincing mechanism does not prevent either outcome. A candidate may fail because it is unsafe, because the effect is smaller than expected, because the endpoint misses the proposed benefit, or because an apparent effect exists only in a subgroup the trial was not designed to identify.51

A real example: CEP-1347 in Parkinson disease

Cell and animal work supported the idea that inhibiting mixed-lineage kinases could protect vulnerable neurons. The PRECEPT trial randomly assigned 806 people with early Parkinson disease who did not yet need dopaminergic therapy to one of three CEP-1347 dose groups or matching placebo; participants were assessed without knowing assignment. Its clinical question was whether treatment delayed the need for dopaminergic therapy. After an average of 21.4 months, a planned interim analysis found it would be futile to continue the experimental treatment, and the trial found no evidence of the intended clinical benefit.

That result is evidence about the tested intervention, regimens, population and endpoint. It does not show that the pathway was irrelevant in every context or that the animal experiments were worthless. The trial alone cannot establish whether an imperfect model, insufficient target engagement, intervention at the wrong stage, or another explanation accounted for the result.7

Controls can make the claim narrower and stronger

Small preclinical studies can produce unstable estimates. Selective reporting, unblinded assessment, flexible outcome choices, inadequate randomisation, and failure to reproduce a result independently can all inflate an apparent effect without requiring misconduct. Vehicle controls, positive controls, blinded assessment, randomisation, prespecified outcomes, adequate sample size and independent replication help separate a robust signal from a fragile one. A result that survives these tests is stronger, but it remains evidence in that model.9

Follow the chain of questions

A translation claim is easier to assess when each link is visible. Did the human exposure engage the intended target? Was treatment started at a disease stage when that mechanism could plausibly matter? Was the clinical outcome prespecified and important to patients? Did the study have a credible comparator, adequate follow-up and a plan for missing data? Were harms and tolerability measured alongside benefit? These are questions for evaluating the evidence, not a universal sequence that every development programme must follow. A missing answer limits the conclusion; it does not automatically explain why a particular study failed.38

Stopping is also information

Development is not a progress bar that inevitably fills. A programme may stop, change direction or require a different study. A negative trial can narrow a claim without answering every biological question; an early positive signal can be overturned by a larger or better-controlled study. Reporting those outcomes helps the reader understand the scientific question rather than simply follow a success narrative.6

Read “promising” as an invitation to ask more

Promising in what model? At what exposure? Compared with what? With which harms measured? What result would be needed next? Does the evidence support a mechanism, a safety decision, a clinical benefit, or only a reason to study the question further? These questions do not dismiss the research. They locate it.

Target engagement is a bridge, not a verdict

A translational programme can ask whether a candidate reached and changed its intended target in people. That bridge may use a biomarker, an imaging signal, a concentration measurement or a physiological response. Each answers a narrower question than ‘did patients get better?’ A target can be engaged without producing a useful clinical effect, and a negative biomarker result can reflect the dose, timing, tissue access or assay rather than disprove the biology. Keep the chain visible: exposure, target engagement, biological response and patient-important outcome are related measurements, not interchangeable proof.134

Further reading

Trusted external resources selected to help explain this page. They open in a new tab.

Sources, kept close.

Selected supporting sources; this is not a complete literature review.

  1. The Drug Development ProcessUS Food and Drug Administration · Regulator explanationAccess checked 2026-11-03 · FDA overview page retrieved and inspected through web access; its five stages are a simplified U.S. development framework.
  2. What Happens to Medicine in Your Body?NIH / NIGMS · Official scientific explainerAccessed 2026-11-03 · Source date: 2023-09-11
  3. Step 3: Clinical ResearchUS Food and Drug Administration · Regulator explanationAccess checked 2026-11-03 · FDA clinical-research page retrieved and inspected through web access for protocol design and the typical phases of drug research.
  4. Surrogate Endpoint Resources for Drug and Biologic DevelopmentU.S. Food and Drug Administration · Regulator endpoint methodology resourceAccess checked 2026-11-03 · FDA surrogate-endpoint resource was inspected through the official indexed page; the canonical page endpoint returned 404 in this environment, while indexed FDA text defines surrogate use and case-by-case interpretation.
  5. How Do Medicines Work?NIH / NIGMS · Official scientific explainerAccessed 2026-11-03 · Source date: 2023-10-16
  6. Development & Approval Process: DrugsUS Food and Drug Administration · Regulator explanationAccess checked 2026-11-03 · FDA development and approval overview retrieved and inspected through web access; it is a U.S. process overview, not product-specific approval evidence.
  7. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson diseaseParkinson Study Group PRECEPT Investigators / Neurology · Peer-reviewed randomised clinical trialAccessed 2026-11-03 · Source date: 2007-10-09
  8. M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for PharmaceuticalsICH / US Food and Drug Administration · International regulator guidanceAccessed 2026-11-03 · Source date: 2010-06
  9. Recommendations for robust and reproducible preclinical research in personalised medicinePeer-reviewed review · Translational research reviewAccessed 2026-11-03